{"entity":{"id":"nct02934568","kind":"trial","name":"Ribociclib (LEE011) Rollover Study for Continued Access","aka":[],"tldr":"A phase 2 trial of LEE011 in advanced solid tumours, run by Novartis Pharmaceuticals, active and no longer recruiting.","summary":"Ribociclib (LEE011) Rollover Study for Continued Access is a phase 2 interventional study registered as NCT02934568 by Novartis Pharmaceuticals, with 22 participants enrolled, started 2016-12-15 and due to reach its primary completion in 2027-02-01. Interventions recorded: LEE011.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02934568","url":"https://clinicaltrials.gov/study/NCT02934568"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["advanced-accelerator-applications"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT02934568","phase":"2","setting":"An Open-label, Multi-center Rollover Protocol for Patients Who Have Participated in a Novartis-sponsored Ribociclib (LEE011) Study and Are Continuing to Benefit From Ribociclib as Single Agent or in Combination With Other Investigational Treatments","sponsor":"Novartis Pharmaceuticals","enrolled":22,"outcomes":[]},"route":"/trials/nct02934568/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"advanced-accelerator-applications","kind":"company","name":"Advanced Accelerator Applications (Novartis)","route":"/companies/advanced-accelerator-applications/"}]}}